Abbott Laboratories

NYSE:ABT

Medical - Devices

Healthcare
$104.48 -0.58%

-$0.51 today

Market cap
$180.95B
Beta
0.62
P/E (TTM)
24.5
EPS (TTM)
$3.59
Dividend yield
2.77%
52W Low $81.97High $139.06

Volume 7.02M

Average 13.17M

ABT Income Before Tax

Profit after all operating and non-operating items but before income tax.

Abbott LaboratoriesNYSE: ABT

Income Before Tax · Q3 FY2026 · quarter ended Sep 2026

Income before tax declines year over year

Q3 FY2026 income before tax of $1.23B fell 43.5% year over year, behind the -19.4% change in trailing-twelve-month income before tax. Sequentially, it fell 19.2% from the prior quarter. Over 3 fiscal years it compounded at +0.6% a year.

Context

  • Income before tax amounted to 19.1% of revenue in FY2025, up 2.4 pp from a year earlier.
  • Income before tax increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -43.5% toward the trailing-twelve-month pace of -19.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$1.23B-19.2% QoQ
Last fiscal yearDec 2025
$8.47B+20.7% YoY
LTMSep 2026
$6.56B-19.4% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-43.5%——
1 year+20.7%——
3-year CAGR+0.6%——
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
8.47B USD
Year-over-year change
+20.7%
4-year CAGR
+0.8%

Income Before Tax vs competitors

How ABT compares with its peers on the latest reported figures

  • ABT's LTM Sep 2026 income before tax of $6.56B is the 4th highest of the 10 companies compared; the peer median is $4.82B.
  • Its year-over-year change of -19.4% is the 8th highest of 10, against a peer median of +10.5%.
  • Income before tax amounts to 13.6% of revenue for ABT, versus a peer median of 17.9%.
ABT Competitors Peer median
Income Before Tax for ABT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$17.74B -43.7%+18.9%17.9%
TMOThermo Fisher Scientific Inc.LTM Sep 2026$7.87B +10.5%-1.8%16.6%
MDTMedtronic plcLTM Jul 2026$6.6B +16.6%+4.6%17.6%
ABTAbbott LaboratoriesLTM Sep 2026$6.56B -19.4%+0.6%13.6%
SYKStryker CorporationLTM Jun 2026$5.15B +53.6%+18.9%19.9%
DHRDanaher CorporationLTM Sep 2026$4.82B +15.4%-16.0%18.8%
BSXBoston Scientific CorporationLTM Jun 2026$3.86B +28.7%+43.7%18.4%
GEHCGE HealthCare Technologies Inc.LTM Jun 2026$2.04B -27.0%+3.3%10.1%
BDXBecton, Dickinson and CompanyLTM Sep 2026$1.98B +5.3%+2.8%9.8%
EWEdwards Lifesciences CorporationLTM Jun 2026$1.42B -12.9%-10.4%21.8%
Peer median (excluding ABT) $4.82B+10.5%+3.3%17.9%

Competitors are the stored peer set for ABT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue43.08B43.65B40.11B41.95B44.33B
Cost of Revenue19.86B21.33B20.07B20.63B19.72B
Gross Profit23.21B22.32B20.04B21.33B24.61B
Gross Margin53.9%51.1%50.0%50.8%55.5%
Research & Development2.74B2.85B2.72B2.82B2.96B
Selling, General & Admin11.28B11.11B10.88B11.65B12.38B
Operating Expenses14.01B13.96B13.6B14.47B16.59B
Depreciation & Amortization3.54B3.27B3.24B3.22B3.12B
EBITDA12.16B11.89B10.61B10.83B11.92B
EBITDA Margin28.2%27.2%26.4%25.8%26.9%
Operating Income9.2B8.36B6.44B6.83B8.05B
Operating Margin21.4%19.2%16.0%16.3%18.2%
Interest Income43M183M385M344M230M
Interest Expense410M315M698M603M341M
Other Income / Expenses(989M)(56M)229M188M418M
Income Before Tax8.21B8.31B6.66B7.01B8.47B
Pre-Tax Margin19.1%19.0%16.6%16.7%19.1%
Income Tax Expense1.14B1.37B941M(6.39B)1.94B
Net Income7.07B6.93B5.72B13.4B6.52B
Net Margin16.4%15.9%14.3%31.9%14.7%
EPS (Basic)3.973.943.307.673.74
EPS (Diluted)3.943.913.277.643.72
Weighted Avg Shares1.78B1.75B1.73B1.73B1.75B
Weighted Avg Shares (Diluted)1.79B1.76B1.75B1.75B1.75B

Abbott Laboratories

NYSE:ABT

Intrinsic Alpha fair value

Locked

Current Price

$104.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.